Objective: Investigate Mogrol's impact on NSCLC radiosensitivity and underlying mechanisms using various methods including assays, bioinformatics, and xenograft models.
Methods: CCK-8, clonogenic, flow cytometry, TUNEL, and Western blot assays evaluated Mogrol and radiation effects on NSCLC viability and apoptosis. USP22 expression in NSCLC patient tissues was determined using RT-qPCR and Western blot. A xenograft model validated Mogrol's effects on tumor growth.
Results: Bioinformatics identified four ubiquitin-specific proteases, including USP22, in NSCLC. Kaplan-Meier analysis confirmed USP22's value in lung cancer survival. HPA database indicated higher USP22 expression in lung cancer tissues. GO and KEGG analysis implicated ERK1/2 in NSCLC progression, and molecular docking showed stability between Mogrol and ERK1/2. Further in vivo and in vitro experiments have demonstrated that Mogrol enhances the inhibitory effect of radiation on NSCLC cell viability and clonogenic capacity. Cell viability and clonogenic capacity are reduced by more than 50%, and an increase in cellular apoptosis is observed, with apoptotic levels reaching 10%. USP22 expression was significantly elevated in NSCLC tissues, particularly in radiotherapy-resistant patients. Mogrol downregulated USP22 expression by inhibiting the ERK/CREB pathway, lowering COX2 expression. Mogrol also enhanced radiation's inhibition of tumor growth in mice.
Conclusion: Mogrol enhances NSCLC radiosensitivity by downregulating USP22 via the ERK/CREB pathway, leading to reduced COX2 expression.
Keywords: ERK/CREB Pathway; Mogrol; Non-Small Cell Lung Cancer; Radiosensitivity; USP22.